Overview

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)

Status:
Not yet recruiting

Trial end date:
2026-11-10

Target enrollment:

Participant gender:

Summary

In this study, Chinese participants with MSI-H or dMMR advanced colorectal cancer will be assigned to receive either pembrolizumab or the Investigator's choice of 1 of 6 standard of care (SOC) chemotherapy regimens for treatment. There is no hypothesis for this study.

Phase:

Phase 3

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Bevacizumab
Cetuximab
Fluorouracil
Irinotecan
Leucovorin
Oxaliplatin
Pembrolizumab